GeneDx (NASDAQ:WGS) Shares Up 4.2% – What’s Next?

Posted by Brenda Bartman on Sep 15th, 2026

GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) shares were up 4.2% on Tuesday . The stock traded as high as $92.91 and last traded at $93.4860. Approximately 134,497 shares traded hands during mid-day trading, a decline of 86% from the average session volume of 931,665 shares. The stock had previously closed at $89.74.

Analysts Set New Price Targets

A number of analysts recently commented on WGS shares. BTIG Research reaffirmed a “buy” rating and issued a $90.00 target price on shares of GeneDx in a research report on Tuesday, August 4th. Zacks Research upgraded GeneDx from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 26th. Canaccord Genuity Group raised their price objective on GeneDx from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Guggenheim restated a “buy” rating and set a $74.00 price objective (up from $70.00) on shares of GeneDx in a report on Monday, June 29th. Finally, Weiss Ratings raised GeneDx from a “sell (e+)” rating to a “sell (d)” rating in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $89.57.

Check Out Our Latest Stock Analysis on WGS

GeneDx Stock Performance

The company’s 50-day simple moving average is $75.09 and its 200 day simple moving average is $66.70. The company has a current ratio of 3.30, a quick ratio of 3.06 and a debt-to-equity ratio of 0.40. The stock has a market cap of $2.88 billion, a P/E ratio of -26.52 and a beta of 1.99.

GeneDx (NASDAQ:WGS – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.20. GeneDx had a negative net margin of 23.41% and a positive return on equity of 4.12%. The company had revenue of $114.44 million during the quarter, compared to analyst estimates of $111.01 million. During the same quarter in the prior year, the business earned $0.36 earnings per share. As a group, sell-side analysts expect that GeneDx Holdings Corp. will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Kevin Feeley sold 1,285 shares of the stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $84.22, for a total value of $108,222.70. Following the sale, the chief financial officer owned 41,476 shares in the company, valued at approximately $3,493,108.72. This trade represents a 3.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 3,692 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $84.22, for a total transaction of $310,940.24. Following the completion of the sale, the chief executive officer directly owned 107,227 shares in the company, valued at $9,030,657.94. This represents a 3.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 25.17% of the stock is currently owned by insiders.

Institutional Investors Weigh In On GeneDx

A number of hedge funds have recently made changes to their positions in WGS. Ramirez Asset Management Inc. bought a new stake in shares of GeneDx in the 4th quarter valued at about $33,000. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in GeneDx in the fourth quarter worth about $35,000. Fifth Third Bancorp bought a new position in shares of GeneDx during the first quarter valued at $31,000. Nykredit A S bought a new stake in shares of GeneDx during the second quarter valued at approximately $38,000. Finally, OP Asset Management Ltd bought a new stake in GeneDx in the 1st quarter worth about $45,000. 61.72% of the stock is currently owned by institutional investors.

GeneDx Company Profile

(Get Free Report)

GeneDx Holdings Corp., doing business as GeneDx, is a healthcare company focused on genetic testing and genomic diagnostics. The company provides testing designed to help healthcare professionals diagnose rare and inherited conditions, guide clinical management, and support research into genetic disease.

Its offerings include whole exome and whole genome sequencing, targeted genetic tests, chromosomal microarray analysis, and other tests used to identify disease-causing genetic variants.